Chelsea Therapeutics (United States)

Chelsea Therapeutics, acquired by Lundbeck, was a pharmaceutical company focused on autonomic dysfunction treatments. The company developed Northera (droxidopa) for neurogenic orthostatic hypotension (NOH), a debilitating blood pressure drop upon standing associated with Parkinson’s disease, multiple system atrophy, and autonomic failure. Lundbeck continues developing treatments for neurological disorders.